Aytu completes safety study in critically ill COVID-19 patients

 

• Aytu BioScience (NASDAQ:AYTU) is up 4.3% in premarket trading as the company announces the completion of the safety study for the use of ultraviolet A light as a COVID-19 treatment.
• The single-center, U.S.-based study evaluated the safety and proof of principle of Aytu’s Healight™ ultraviolet A light catheter technology in newly intubated critically ill COVID-19 patients on mechanical ventilation.
• The data collected will be submitted to the FDA as part of the review process for Healight as a COVID-19 treatment, a statement from the company said.
• The Healight technology platform uses Aytu’s proprietary methods for administering intermittent ultraviolet A light via a respiratory tract device. The preclinical findings have indicated it has significantly reduced a wide range of viral and bacterial loads, including the coronavirus HCoV-229E linked to the common cold.
• With the company having worldwide licensing rights to develop the Healight™ technology platform, Seeking Alpha contributor, Swich Research, estimates a $775 million market opportunity for the device.
• https://seekingalpha.com/news/3647495-aytu-bioscience-completes-safety-study-in-critically-ill-covidminus-19-patients